
-
Kremlin says Putin, Trump to hold 'one-on-one' talks in Alaska
-
Stocks diverge as bitcoin hits record high
-
Spain suffers third wildfire death, Greece beats back flames
-
Liverpool 'agree deal' for Parma prospect Leoni
-
Foreign NGOs say new Israeli rules keep them from delivering Gaza aid
-
Japan's grand tea master Sen Genshitsu dies at 102: reports
-
Water shortages plague Beirut as low rainfall compounds woes
-
Germany's Thyssenkrupp cuts targets as US tariffs weigh
-
Brady didn't understand football, says Rooney after 'work ethic' jibe
-
Greek firefighters make progress against wildfires
-
UK economy slows less than feared after tariffs
-
Markets mixed as bitcoin hits new high
-
PSG begin French title defence as Pogba returns home and Paris FC step up
-
At least 40 dead in Sudan's worst cholera outbreak in years: MSF
-
Zelensky in London to meet PM ahead of US-Russia summit
-
French dictionary gets bad rap over Congolese banana leaf dish
-
Alaska: a source of Russian imperial nostalgia
-
Last chance saloon for global plastic pollution treaty
-
India to bid for Commonwealth Games as part of Olympic push
-
North Korea denies removing border loudspeakers
-
Despite risks, residents fight to protect Russian national park
-
Asian markets mixed as bitcoin surges to new high
-
War-weary Ukrainians find solace by frontline lake
-
Okinawa a reluctant host for US troops 80 years after WWII
-
Alonso's Real Madrid start La Liga with fresh energy
-
Liverpool splash out to secure status as Premier League's top dogs
-
Hong Kong court postpones closing arguments in Jimmy Lai trial
-
Top Japanese fighter retires to support comatose boxer brother
-
Boars, Butterflies or Bees? Public to name Papua New Guinea's NRL team
-
Defending champions Sinner, Sabalenka reach Cincinnati quarters
-
Bolivia presidential hopefuls make last push for votes
-
Trump orders space regulations eased in win for Musk
-
From Snoop Dogg to Tom Brady, stars flock to English second-tier clubs
-
Inside Trump's 'Alligator Alcatraz': detainees allege abuse in a legal black hole
-
Scientists find surprising sex reversal in Australian birds
-
Taylor Swift sets October release for new album
-
Oh carp: UK's Lammy on the hook after fishing with Vance without licence
-
ANITA & ZAHA Introduces Exclusive "Made in France" Natural Cosmetics
-
Sinner shrugs off rain to dispatch Mannarino in Cincinnati
-
Tainted fentanyl blamed for 87 hospital deaths in Argentina
-
Eyeing robotaxis, Tesla hiring New York test car operator
-
NBA approves $6.1bn sale of Boston Celtics
-
Cowboys owner Jones says experimental drug saved him after cancer diagnosis
-
Striking Boeing defense workers turn to US Congress
-
PSG beat Tottenham on penalties to win UEFA Super Cup
-
Hong Kong court to hear closing arguments in mogul Jimmy Lai's trial
-
US singer Billy Joel to sell off motorcycles due to health condition
-
Barcelona's Ter Stegen validated as long-term injury by La Liga
-
Storm makes landfall in China after raking Taiwan as typhoon
-
Colombia buries assassinated presidential candidate

US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Schubert--BTB